SCHEMBL4254670

SCHEMBL4254670

CCCCCNNC(=O)c1ccco1

nearest known ligand 0.91

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 8/20 0.91
▸ GAA P10253 1/20 0.63
▸ ALDH1A1 P00352 3/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ PKM P14618 1/20 0.58
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ HDAC1 Q13547 6/20 0.52
▸ HDAC2 Q92769 5/20 0.52
▸ HDAC8 Q9BY41 2/20 0.52
▸ HDAC11 Q96DB2 1/20 0.52
▸ HDAC6 Q9UBN7 1/20 0.52
▸ TSHR P16473 2/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ POLB P06746 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27345911 0.95 HDAC3 (1.00) HDAC3GAAALDH1A1SMN1; SMN2PKM
SCHEMBL14996212 0.84 SMN1; SMN2 (0.81) HDAC3GAAALDH1A1SMN1; SMN2PKM
SCHEMBL2719119 0.83 SMN1; SMN2 (0.84) HDAC3GAAALDH1A1SMN1; SMN2PKM
SCHEMBL9784444 0.83 SMN1; SMN2 (0.84) HDAC3GAAALDH1A1SMN1; SMN2PKM
SCHEMBL15999997 0.83 SMN1; SMN2 (0.84) HDAC3GAAALDH1A1SMN1; SMN2PKM
SCHEMBL3092684 0.80 ALDH1A1 (0.81) HDAC3GAAALDH1A1SMN1; SMN2PKM
SCHEMBL12666949 0.79 HPGD (0.63) HDAC3GAAALDH1A1SMN1; SMN2PKM
SCHEMBL9110035 0.78 SMN1; SMN2 (0.71) HDAC3ALDH1A1SMN1; SMN2PKMMEN1
SCHEMBL9303459 0.76 HDAC3 (0.55) HDAC3GAAALDH1A1SMN1; SMN2PKM
SCHEMBL6361865 0.76 ALDH1A1 (0.74) HDAC3GAAALDH1A1SMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 — — US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 — — US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 HDAC3 466/4885GAA 1023/4885ALDH1A1 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback